↓ Skip to main content

The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data

Overview of attention for article published in Parasites & Vectors, March 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (80th percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

twitter
8 tweeters
wikipedia
1 Wikipedia page

Readers on

mendeley
66 Mendeley
Title
The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data
Published in
Parasites & Vectors, March 2015
DOI 10.1186/s13071-015-0779-4
Pubmed ID
Authors

Hugo C Turner, Martin Walker, Simon K Attah, Nicholas O Opoku, Kwablah Awadzi, Annette C Kuesel, María-Gloria Basáñez

Abstract

Spurred by success in several foci, onchocerciasis control policy in Africa has shifted from morbidity control to elimination of infection. Clinical trials have demonstrated that moxidectin is substantially more efficacious than ivermectin in effecting sustained reductions in skin microfilarial load and, therefore, may accelerate progress towards elimination. We compare the potential cost-effectiveness of annual moxidectin with annual and biannual ivermectin treatment. Data from the first clinical study of moxidectin were used to parameterise the onchocerciasis transmission model EPIONCHO to investigate, for different epidemiological and programmatic scenarios in African savannah settings, the number of years and in-country costs necessary to reach the operational thresholds for cessation of treatment, comparing annual and biannual ivermectin with annual moxidectin treatment. Annual moxidectin and biannual ivermectin treatment would achieve similar reductions in programme duration relative to annual ivermectin treatment. Unlike biannual ivermectin treatment, annual moxidectin treatment would not incur a considerable increase in programmatic costs and, therefore, would generate sizeable in-country cost savings (assuming the drug is donated). Furthermore, the impact of moxidectin, unlike ivermectin, was not substantively influenced by the timing of treatment relative to seasonal patterns of transmission. Moxidectin is a promising new drug for the control and elimination of onchocerciasis. It has high programmatic value particularly when resource limitation prevents a biannual treatment strategy, or optimal timing of treatment relative to peak transmission season is not feasible.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 66 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 3%
Indonesia 1 2%
Ghana 1 2%
Unknown 62 94%

Demographic breakdown

Readers by professional status Count As %
Researcher 17 26%
Student > Ph. D. Student 12 18%
Student > Bachelor 9 14%
Lecturer 6 9%
Student > Master 6 9%
Other 12 18%
Unknown 4 6%
Readers by discipline Count As %
Medicine and Dentistry 13 20%
Agricultural and Biological Sciences 13 20%
Immunology and Microbiology 7 11%
Biochemistry, Genetics and Molecular Biology 5 8%
Social Sciences 5 8%
Other 17 26%
Unknown 6 9%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 November 2017.
All research outputs
#1,776,825
of 12,093,596 outputs
Outputs from Parasites & Vectors
#370
of 3,059 outputs
Outputs of similar age
#41,690
of 218,267 outputs
Outputs of similar age from Parasites & Vectors
#9
of 87 outputs
Altmetric has tracked 12,093,596 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,059 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 218,267 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 87 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.